

fulvestrant (Faslodex[®])
AstraZeneca UK

No. 114/04

Summary of Advice

9 August 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

Advice: following a full submission.

Fulvestrant is not recommended for use within NHS Scotland for the treatment of postmenopausal women with advanced breast cancer who relapse or progress following prior anti-oestrogen therapy. Fulvestrant is no more effective than aromatase inhibitors when used following the failure of tamoxifen, and it is approximately four times more expensive. There are no randomised clinical data on the use of fulvestrant following failure of aromatase inhibitors.

The licence holder has indicated their decision to resubmit.

Professor David H Lawson
Chairman